Compare EXP & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXP | PTCT |
|---|---|---|
| Founded | 1963 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.0B |
| IPO Year | 1994 | 2006 |
| Metric | EXP | PTCT |
|---|---|---|
| Price | $191.66 | $69.17 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 17 |
| Target Price | ★ $227.11 | $80.65 |
| AVG Volume (30 Days) | 294.1K | ★ 735.7K |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | ★ 3.29 | 0.90 |
| Revenue | ★ $495,023,000.00 | $264,734,000.00 |
| Revenue This Year | $1.97 | N/A |
| Revenue Next Year | $1.95 | $17.70 |
| P/E Ratio | ★ $59.11 | $77.00 |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $171.99 | $57.74 |
| 52 Week High | $245.53 | $90.87 |
| Indicator | EXP | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 40.63 |
| Support Level | $188.79 | $67.57 |
| Resistance Level | $226.04 | $70.01 |
| Average True Range (ATR) | 5.14 | 2.08 |
| MACD | -0.72 | 0.00 |
| Stochastic Oscillator | 10.69 | 27.43 |
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.